Minerva Neurosciences (NERV) to Release Earnings on Tuesday

Minerva Neurosciences (NASDAQ:NERV) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, February 23, 2026 at 9:30 AM ET.

Minerva Neurosciences Stock Down 0.3%

Minerva Neurosciences stock opened at $6.27 on Tuesday. Minerva Neurosciences has a 12 month low of $1.15 and a 12 month high of $12.46. The stock has a market cap of $271.30 million, a P/E ratio of -3.39 and a beta of -0.22. The company’s fifty day simple moving average is $4.44 and its 200-day simple moving average is $3.46.

Wall Street Analyst Weigh In

NERV has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Monday, December 29th. Wall Street Zen downgraded Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Finally, HC Wainwright reduced their target price on shares of Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $4.00.

Institutional Trading of Minerva Neurosciences

A number of institutional investors and hedge funds have recently modified their holdings of NERV. Federated Hermes Inc. boosted its holdings in shares of Minerva Neurosciences by 297.5% during the 4th quarter. Federated Hermes Inc. now owns 5,371,775 shares of the biopharmaceutical company’s stock worth $21,595,000 after buying an additional 4,020,500 shares during the period. Vivo Capital LLC acquired a new position in Minerva Neurosciences during the 4th quarter worth $17,377,000. Renaissance Technologies LLC boosted its holdings in Minerva Neurosciences by 28.1% during the fourth quarter. Renaissance Technologies LLC now owns 149,200 shares of the biopharmaceutical company’s stock valued at $600,000 after acquiring an additional 32,700 shares during the period. Finally, State Street Corp grew its position in shares of Minerva Neurosciences by 45.4% in the fourth quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 7,500 shares during the last quarter. 34.56% of the stock is currently owned by institutional investors and hedge funds.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.